Exicure Accounts Payable Over Time
| XCUR Stock | USD 18.38 7.52 69.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Exicure Performance and Exicure Correlation. Exicure |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exicure. If investors know Exicure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exicure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 0.289 | Quarterly Revenue Growth 9.28 | Return On Assets (0.26) | Return On Equity (1.44) |
The market value of Exicure is measured differently than its book value, which is the value of Exicure that is recorded on the company's balance sheet. Investors also form their own opinion of Exicure's value that differs from its market value or its book value, called intrinsic value, which is Exicure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exicure's market value can be influenced by many factors that don't directly affect Exicure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exicure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exicure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exicure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Exicure and related stocks such as Ikena Oncology, Eliem Therapeutics, and HCW Biologics Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IKNA | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 935 K | 2.1 M | 2.4 M | 2.1 M | 2.1 M | 2.2 M |
| HCWB | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 392.3 K | 155.3 K | 223.7 K | 1.2 M | 6.2 M | 6.5 M |
| RNXT | 538 K | 538 K | 538 K | 538 K | 538 K | 538 K | 538 K | 538 K | 538 K | 538 K | 162 K | 525 K | 534 K | 561 K | 510.4 K |
| TPST | 875 K | 875 K | 875 K | 1.7 M | 2.5 M | 3.4 M | 2.2 M | 2.2 M | 2 M | 1.5 M | 1.1 M | 991 K | 1.1 M | 845 K | 1.4 M |
| SCPH | 684 K | 684 K | 684 K | 684 K | 684 K | 684 K | 1.5 M | 1.6 M | 587 K | 1.1 M | 1.7 M | 544 K | 1.5 M | 4 M | 4.2 M |
| MIST | 819 K | 819 K | 819 K | 819 K | 819 K | 819 K | 819 K | 819 K | 2.6 M | 4.4 M | 4.6 M | 4.4 M | 2.3 M | 4 M | 3.6 M |
| ONCY | 86.1 K | 6.4 M | 7.3 M | 6 M | 3.4 M | 2.7 M | 4.1 M | 3.7 M | 1.8 M | 3.2 K | 1.8 K | 594 K | 2.3 M | 1.1 M | 1 M |
| MCRB | 112 K | 112 K | 112 K | 393 K | 2.2 M | 5.4 M | 7.6 M | 7 M | 6.4 M | 4.9 M | 4 M | 13.7 M | 17.4 M | 3.6 M | 6.7 M |
| LUMO | 601 K | 1.7 M | 972 K | 3.5 M | 2.4 M | 12.4 M | 22.9 M | 9.3 M | 555 K | 475 K | 244 K | 612 K | 275 K | 890 K | 845.5 K |
| MRKR | 106.8 K | 794.3 K | 1.7 M | 1.5 M | 620.8 K | 967.4 K | 680.2 K | 1 M | 1.6 M | 993 K | 2.9 M | 5.1 M | 1.1 M | 961 K | 1.3 M |
| PTIX | 189 K | 189 K | 15.6 M | 189 K | 138 K | 168 K | 13.4 | 161 | 52.4 K | 36.2 K | 141.9 K | 279 K | 155.5 K | 113.8 K | 108.1 K |
| PMVP | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 2.8 M | 1.6 M | 3.2 M | 3 M | 3.2 M | 2.7 M |
| IMNN | 197.2 K | 5.2 M | 3.6 M | 1.5 M | 3.5 M | 2.8 M | 5.4 M | 3.4 M | 3 M | 2.9 M | 2.2 M | 2.5 M | 3.6 M | 3.5 M | 2.4 M |
| CYCC | 954 K | 1.8 M | 2.3 M | 2.5 M | 2.8 M | 1.9 M | 2.5 M | 1.6 M | 2.7 M | 890 K | 514 K | 2.1 M | 2.6 M | 3.5 M | 2.2 M |
| HSTO | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 3 M | 692 K | 692 K | 692 K | 315 K | 808 K | 539 K | 1.4 M | 382 K | 343.8 K | 326.6 K |
| DMAC | 665.3 K | 139.3 K | 1.2 M | 372.1 K | 960 K | 672.4 K | 326.6 K | 513 K | 483 K | 182 K | 1.1 M | 509 K | 734 K | 926 K | 563.1 K |
Exicure and related stocks such as Ikena Oncology, Eliem Therapeutics, and HCW Biologics Accounts Payable description
An accounting item on the balance sheet that represents Exicure obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Exicure are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Exicure | XCUR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Illinois; U.S.A |
| Exchange | NASDAQ Exchange |
USD 18.38
Additional Tools for Exicure Stock Analysis
When running Exicure's price analysis, check to measure Exicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exicure is operating at the current time. Most of Exicure's value examination focuses on studying past and present price action to predict the probability of Exicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exicure's price. Additionally, you may evaluate how the addition of Exicure to your portfolios can decrease your overall portfolio volatility.